Clinical Trial Update: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating JMT101 with docetaxel in squamous cell non-small cell lung cancer; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• JMT101

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Squamous Cell Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING